BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 405,200 shares, a decline of 43.4% from the February 28th total of 715,900 shares. Currently, 8.1% of the shares of the stock are short sold. Based on an average trading volume of 371,800 shares, the days-to-cover ratio is currently 1.1 days.

Institutional Investors Weigh In On BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. Citadel Advisors LLC bought a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned about 0.31% of BioRestorative Therapies at the end of the most recent quarter. Institutional investors and hedge funds own 69.38% of the company’s stock.

BioRestorative Therapies Trading Down 1.1 %

BRTX stock opened at $1.81 on Friday. The firm has a 50-day moving average price of $1.97 and a 200-day moving average price of $1.72. BioRestorative Therapies has a 12 month low of $1.03 and a 12 month high of $2.55. The stock has a market capitalization of $12.53 million, a P/E ratio of -1.18 and a beta of 64.37.

BioRestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.07. The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.48 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%. As a group, equities analysts predict that BioRestorative Therapies will post -1.43 EPS for the current fiscal year.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.